The current generation of cell therapies has proven a game changer in terms of treating aggressive blood cancers, but the tech has its limitations. Novartis, one of the biggies in the current…
Relaxation apps have nothing on AbbVie migraine med Ubrelvy’s TikTok. Ocean waves and birds chirping offer respite and a quiet scrolling break on the more typically frenetic social media app. AbbVie…
CAR-Ts targeting CD19 — like Yescarta, Kymriah and the recently approved Breyanzi — have shifted the paradigm for the treatment of B cell lymphoma, according to Sairah Ahmed, a longtime researcher in…
Four months after its first upbeat interim analysis, Shanghai’s Junshi Biosciences and California biotech Coherus BioSciences are touting a statistically significant improvement in overall survival…
Gene therapy biotech Intellia Therapeutics has dosed its first patient with genome editing candidate NTLA-2002, its drug candidate for hereditary angioedema, a rare genetic condition that causes…
Merck’s potential Covid-19 treatment molnupiravir will not be used in France, French regulators said Friday. The French National Authority of Health cited the potential impact of the Omicron variant,…
After more than two decades in the clinic, Atara Biotherapeutics’ T cell therapy tabelecleucel is finally headed to the FDA — but not without a pivotal readout at this year’s ASH conference. About…
Do investors want the good news, or the bad news first? Bellus went with the good news, sharing that its chronic cough contender hit the primary endpoint in a Phase IIb trial, lining it up for a Phase…
In the face of short attacks, it is not uncommon these days for companies to cry foul and defend themselves against what they call false and misleading statements. But are these short sellers involved…
Soon after San Francisco-based Genentech won an EUA for tocilizumab as a treatment for hospitalized Covid patients last summer, the company announced a shortage of the drug while pointing to the…
